Related Experiment Video
Updated: Jan 28, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
[Therapy of Hypercholesterolemia in Primary Prevention]
Insights
Low-density lipoprotein-cholesterol (LDL-C) drives cardiovascular disease. This review explores LDL-C lowering strategies for primary prevention, balancing benefits and risks.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Lipidology
Background:
- Atherosclerotic cardiovascular disease (ASCVD) is a major global health burden.
- Dyslipidemia, particularly elevated low-density lipoprotein-cholesterol (LDL-C), is a key driver of ASCVD.
- Establishing causality of LDL-C in ASCVD pathophysiology is critical for prevention.
Purpose of the Study:
- To review current evidence on LDL-C lowering for cardiovascular disease primary prevention.
- To discuss guideline recommendations and clinical strategies for managing LDL-C in primary prevention.
- To address controversies regarding patient selection, benefit magnitude, and potential harm in primary prevention.
Main Methods:
- Literature review of current evidence and guideline recommendations.
- Analysis of strategies for lowering LDL-C.
- Discussion of controversies in primary prevention.
Main Results:
- Statins are first-line for secondary prevention of hypercholesterolemia.
- Evidence for primary prevention requires careful consideration of individual risk, benefit, and harm.
- Optimal LDL-C targets and treatment thresholds remain subjects of ongoing debate.
Conclusions:
- Lowering LDL-C is crucial for preventing cardiovascular events.
- Personalized risk assessment is essential for guiding primary prevention strategies.
- Further research is needed to refine guidelines for LDL-C management in primary prevention.
Abstract:
Atherosclerotic cardiovascular disease is the leading cause of premature mortality and morbidity worldwide. Dyslipidemia is a commonly encountered clinical condition and is an important determinant of cardiovascular disease. The causality of plasma low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of cardiovascular disease has been established beyond any reasonable doubt. In this context, individual risk estimation, the determination of target values and lipid-lowering strategies represent an essential part and a challenge in the daily clinical practice to prevent cardiovascular events. Statins are recommended as first-line therapy for patients with hypercholesterolemia in secondary prevention. Controversies remain in the context of primary prevention, however, as to which kind of subjects to treat, the magnitude of the benefit, and potential harm. This article gives a brief overview of the current evidence, guideline recommendations and strategies for lowering of LDL-C in the primary prevention of cardiovascular disease.
Related Concept Videos
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Cancer Prevention
Some...
Gene Therapy
Prevention of Further Absorption of Poison
Preventive Healthcare Services
Group Therapy

